End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.67 CNY | -0.69% |
|
-3.77% | -26.09% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.09% | 1.58B | B | ||
+20.76% | 43.77B | B- | ||
+28.00% | 22.83B | B+ | ||
+20.25% | 15.56B | - | ||
+18.82% | 14.34B | B+ | ||
+55.83% | 12.96B | B | ||
-0.05% | 6.79B | - | - | |
-12.70% | 6.41B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.65% | 5.69B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002399 Stock
- Ratings Shenzhen Hepalink Pharmaceutical Group Co., Ltd.